Core Viewpoint - Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. (Meihao Medical) announced a share reduction plan involving its actual controller and some board members, totaling up to 14.2745 million shares, which represents approximately 2.51% of the company's total share capital [1] Group 1: Share Reduction Plan - The share reduction plan involves two main parties: the actual controller's concerted actors, including Shenzhen Meitai Lian Industrial Co., Ltd., holding a total of 26.7020% of shares, planning to reduce up to 14.2202 million shares, accounting for 2.4997% of total share capital [1] - The management team, including board member Joel Chan and three vice presidents, holds a combined 0.0382% of shares and plans to reduce up to 54,300 shares, representing 0.0095% of total share capital [1] Group 2: Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the cumulative net profit attributable to shareholders was 208 million yuan, a year-on-year decrease of 19.25% [1] - The operating cash flow net amount for the first three quarters decreased by 26.43% year-on-year, and accounts receivable increased to 408 million yuan, a year-on-year increase of 26.30% [1] - The company's net profit attributable to shareholders peaked at 258 million yuan in 2023, with a slight decline to 248 million yuan in 2024, representing a year-on-year decrease of 3.87% [2] Group 3: Market Information - As of January 20, the closing price of Meihao Medical was 32.32 yuan per share, with a total market capitalization of 18.39 billion yuan [3]
增收不增利！美好医疗业绩承压，拟遭组团减持